CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target

Leukemia. 2005 Nov;19(11):2021-2. doi: 10.1038/sj.leu.2403948.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / analysis
  • Antigens, CD / biosynthesis*
  • Antigens, Differentiation, Myelomonocytic / analysis
  • Antigens, Differentiation, Myelomonocytic / biosynthesis*
  • Biomarkers, Tumor / analysis
  • Bone Marrow Cells
  • Gemtuzumab
  • Gene Expression Profiling
  • Humans
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / immunology*
  • Plasma Cells
  • Prognosis
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • Biomarkers, Tumor
  • CD33 protein, human
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab